8ATB

Discovery of IRAK4 Inhibitor 16


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.35 Å
  • R-Value Free: 
    0.260 (Depositor), 0.260 (DCC) 
  • R-Value Work: 
    0.212 (Depositor), 0.220 (DCC) 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 

Created with Raphaël 2.3.0Worse 01 BetterLigand structure goodness of fit to experimental dataBest fitted O0HClick on this verticalbar to view details

This is version 1.3 of the entry. See complete history


Literature

Discovery of IRAK4 Inhibitors BAY1834845 (Zabedosertib) and BAY1830839 .

Bothe, U.Gunther, J.Nubbemeyer, R.Siebeneicher, H.Ring, S.Bomer, U.Peters, M.Rausch, A.Denner, K.Himmel, H.Sutter, A.Terebesi, I.Lange, M.Wengner, A.M.Guimond, N.Thaler, T.Platzek, J.Eberspacher, U.Schafer, M.Steuber, H.Zollner, T.M.Steinmeyer, A.Schmidt, N.

(2024) J Med Chem 67: 1225-1242

  • DOI: https://doi.org/10.1021/acs.jmedchem.3c01714
  • Primary Citation of Related Structures:  
    8ATB, 8ATL, 8ATN, 8BR5, 8BR6, 8BR7

  • PubMed Abstract: 

    Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a critical role in innate inflammatory processes. Here, we describe the discovery of two clinical candidate IRAK4 inhibitors, BAY1834845 (zabedosertib) and BAY1830839 , starting from a high-throughput screening hit derived from Bayer's compound library. By exploiting binding site features distinct to IRAK4 using an in-house docking model, liabilities of the original hit could surprisingly be overcome to confer both candidates with a unique combination of good potency and selectivity. Favorable DMPK profiles and activity in animal inflammation models led to the selection of these two compounds for clinical development in patients.


  • Organizational Affiliation

    Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Interleukin-1 receptor-associated kinase 4A [auth AAA],
B [auth BBB]
298Homo sapiensMutation(s): 3 
Gene Names: IRAK4
EC: 2.7.11.1
UniProt & NIH Common Fund Data Resources
Find proteins for Q9NWZ3 (Homo sapiens)
Explore Q9NWZ3 
Go to UniProtKB:  Q9NWZ3
PHAROS:  Q9NWZ3
GTEx:  ENSG00000198001 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ9NWZ3
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Modified Residues  3 Unique
IDChains TypeFormula2D DiagramParent
CSO
Query on CSO
A [auth AAA],
B [auth BBB]
L-PEPTIDE LINKINGC3 H7 N O3 SCYS
SEP
Query on SEP
A [auth AAA],
B [auth BBB]
L-PEPTIDE LINKINGC3 H8 N O6 PSER
TPO
Query on TPO
A [auth AAA],
B [auth BBB]
L-PEPTIDE LINKINGC4 H10 N O6 PTHR
Binding Affinity Annotations 
IDSourceBinding Affinity
O0H BindingDB:  8ATB IC50: 5 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.35 Å
  • R-Value Free:  0.260 (Depositor), 0.260 (DCC) 
  • R-Value Work:  0.212 (Depositor), 0.220 (DCC) 
Space Group: I 2 2 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 87.2α = 90
b = 117.5β = 90
c = 136.6γ = 90
Software Package:
Software NamePurpose
REFMACrefinement
XDSdata reduction
XSCALEdata scaling
MOLREPphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 

Created with Raphaël 2.3.0Worse 01 BetterLigand structure goodness of fit to experimental dataBest fitted O0HClick on this verticalbar to view details

Entry History & Funding Information

Revision History  (Full details and data files)

  • Version 1.0: 2023-11-29
    Type: Initial release
  • Version 1.1: 2024-01-31
    Changes: Database references
  • Version 1.2: 2024-02-07
    Changes: Database references
  • Version 1.3: 2024-11-13
    Changes: Structure summary